Author details

Full Name

Myles Brown

Affiliation

ORCID

Career Start Year

1975

Papers

287

H Index

105

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36993558	Analysis of evolutionary dynamics and clonal architecture in prostate cancer.	bioRxiv	2023
37729434	TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependence.	Sci Transl Med	2023
37971305	Cistrome Data Browser: integrated search, analysisÂ and visualization of chromatin data.		2023
37149682	MetaTiME integrates single-cell gene expression to characterize the meta-components of the tumor immune microenvironment.		2023
36688700	Cistrome Explorer: an interactive visual analysis tool for large-scale epigenomic data.	Bioinformatics	2023
37433791	Multi-batch single-cell comparative atlas construction by deep learning disentanglement.		2023
35304445	p16<sup>INK4A</sup>-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases.	Nat Commun	2022
36240281	Machine learning on syngeneic mouse tumor profiles to model clinical immunotherapy response.	Science advances	2022
36219700	Hippo Signaling Pathway Regulates Cancer Cell-Intrinsic MHC-II Expression.	Cancer Immunology Research	2022
35562350	MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets.	Nat Commun	2022
36068320	MIRA: joint regulatory modeling of multimodal expression and chromatin accessibility in single cells.	Nature Methods	2022
35479411	A chemical probe for BAG1 targets androgen receptor-positive prostate cancer through oxidative stress signaling pathway.	iScience	2022
35603787	Response to supraphysiological testosterone is predicted by a distinct androgen receptor cistrome.	JCI Insight	2022
35031563	Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress.	Proc Natl Acad Sci U S A	2022
34534350	TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response.	Nucleic Acids Res	2022
34496240	Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer.	Cell Rep	2021
33972779	Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence.	Nat Genet	2021
33589424	Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade.	Cancer Discov	2021
34161278	Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening.	Proc Natl Acad Sci U S A	2021
33785741	Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.	Nat Commun	2021
33997789	CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity.	Nat Cancer	2021
33567269	Systematic characterization of mutations altering protein degradation in human cancers.	Mol Cell	2021
34256096	Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells.	Cancer Lett	2021
32859606	Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment.	Cancer Res	2021
33417832	An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence.	Cancer Cell	2021
33158814	Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer.	Cancer Research	2021
34737445	FGFR-inhibitor-mediated dismissal of SWI/SNF complexes from YAP-dependent enhancers induces adaptive therapeutic resistance.	Nat Cell Biol	2021
32723834	Inhibition of MAN2A1 Enhances the Immune Response to Anti-PD-L1 in Human Tumors.	Clin Cancer Res	2020
32374402	Hdac3 is an epigenetic inhibitor of the cytotoxicity program in CD8 T cells.	J Exp Med	2020
32424124	Determinants of transcription factor regulatory range.	Nature Communications	2020
32413516	CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma.	Genomics Proteomics Bioinformatics	2020
32393766	Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer.	Nat Commun	2020
32277005	Premenopausal Plasma Osteoprotegerin and Breast Cancer Risk: A Case-Control Analysis Nested within the Nurses' Health Study II.	Cancer Epidemiol Biomarkers Prev	2020
32441763	Correction: Hdac3 is an epigenetic inhibitor of the cytotoxicity program in CD8 T cells.	J Exp Med	2020
32381587	The Dysregulated Pharmacology of Clinically Relevant Mutants is Normalized by Ligand-activated WT Receptor.	Molecular Cancer Therapeutics	2020
32934023	ERG-Mediated Coregulator Complex Formation Maintains Androgen Receptor Signaling in Prostate Cancer.	Cancer Research	2020
32767996	Integrative analyses of single-cell transcriptome and regulome using MAESTRO.		2020
32704543	Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition.	Sci Adv	2020
33059736	Clonal tracing reveals diverse patterns of response to immune checkpoint blockade.	Genome Biol	2020
30710114	Integrative analysis of pooled CRISPR genetic screens using MAGeCKFlute.		2019
31698248	Androgen Receptor Is a Non-canonical Inhibitor of Wild-Type and Mutant Estrogen Receptors in Hormone Receptor-Positive Breast Cancers.	iScience	2019
31644911	The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer.	Cell Rep	2019
31727847	Deciphering essential cistromes using genome-wide CRISPR screens.	Proc Natl Acad Sci U S A	2019
30604001	Pre-diagnostic sex hormone levels and survival among breast cancer patients.	Breast Cancer Res Treat	2019
30358813	A Bayesian model for single cell transcript expression analysis on MERFISH data.		2019
30445651	Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses' Health Studies.	J Natl Cancer Inst	2019
30462313	Cistrome Data Browser: expanded datasets and new tools for gene regulatory analysis.	Nucleic Acids Research	2019
30875429	A Bayesian model for single cell transcript expression analysis on MERFISH data.		2019
30753830	KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance.	Cancer Cell	2019
31077689	Consideration of breast cancer subtype in targeting the androgen receptor.	Pharmacol Ther	2019